UK markets close in 2 hours 34 minutes
  • FTSE 100

    7,017.56
    -1.97 (-0.03%)
     
  • FTSE 250

    22,559.20
    +37.02 (+0.16%)
     
  • AIM

    1,256.11
    +1.86 (+0.15%)
     
  • GBP/EUR

    1.1591
    +0.0051 (+0.44%)
     
  • GBP/USD

    1.3952
    +0.0113 (+0.81%)
     
  • BTC-GBP

    40,575.23
    +2,177.32 (+5.67%)
     
  • CMC Crypto 200

    1,283.28
    -108.43 (-7.79%)
     
  • S&P 500

    4,185.47
    +15.05 (+0.36%)
     
  • DOW

    34,200.67
    +164.67 (+0.48%)
     
  • CRUDE OIL

    63.27
    +0.14 (+0.22%)
     
  • GOLD FUTURES

    1,777.80
    -2.40 (-0.13%)
     
  • NIKKEI 225

    29,685.37
    +2.00 (+0.01%)
     
  • HANG SENG

    29,106.15
    +136.44 (+0.47%)
     
  • DAX

    15,445.08
    -14.67 (-0.09%)
     
  • CAC 40

    6,314.21
    +27.14 (+0.43%)
     

Updated - Gabriele Cerrone, Chairman of Tiziana Life Sciences to give interview on Bloomberg Television US at 1:50 PM ET Tomorrow, 30 March 2021

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Tiziana Life Sciences Plc
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK and LONDON, March 29, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, clarifies that its Chairman and Founder, Gabriele Cerrone, will be giving an interview on Bloomberg Television on Tuesday, 30 March 2021 at 1.50 p.m. US Eastern Standard Time (6.50 p.m. London) as part of the Bloomberg Markets Show.

This is an amendment to the previous time and date communicated.

About Tiziana Life Sciences

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to Milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.

For further enquiries:

United Kingdom Investors:

Tiziana Life Sciences plc (TLSA)

Gabriele Cerrone, Chairman, and founder

+44 (0)20 7495 2379

U.S. Investor Relations Contact:

RedChip Companies, Inc.

Dave Gentry

1-800 RED-CHIP (733-2447)

Or 407-491-4498

Dave@redchip.com